Sutro Biopharma Management
Management criteria checks 2/4
Sutro Biopharma's CEO is Jane Chung, appointed in Nov 2023, has a tenure of 1.33 years. directly owns 0.12% of the company’s shares, worth $80.91K. The average tenure of the management team and the board of directors is 2 years and 5.2 years respectively.
Key information
Jane Chung
Chief executive officer
n/a
Total compensation
| CEO salary percentage | n/a |
| CEO tenure | 1.3yrs |
| CEO ownership | 0.1% |
| Management average tenure | 2yrs |
| Board average tenure | 5.2yrs |
Recent management updates
Recent updates
Sutro Biopharma, Inc. (NASDAQ:STRO) Not Doing Enough For Some Investors As Its Shares Slump 25%
Mar 04
Sutro Biopharma: I Don't Buy That Their Pipeline Is Worthless
Jan 02Why Investors Shouldn't Be Surprised By Sutro Biopharma, Inc.'s (NASDAQ:STRO) 26% Share Price Plunge
Nov 30Revenues Working Against Sutro Biopharma, Inc.'s (NASDAQ:STRO) Share Price Following 25% Dive
Oct 11Sutro Biopharma's Competitive ADCs Position It For Future Growth In Oncology
Sep 23There's No Escaping Sutro Biopharma, Inc.'s (NASDAQ:STRO) Muted Revenues Despite A 29% Share Price Rise
Aug 24Brokers Are Upgrading Their Views On Sutro Biopharma, Inc. (NASDAQ:STRO) With These New Forecasts
Aug 22Analysts Are Upgrading Sutro Biopharma, Inc. (NASDAQ:STRO) After Its Latest Results
Aug 16The Market Doesn't Like What It Sees From Sutro Biopharma, Inc.'s (NASDAQ:STRO) Revenues Yet As Shares Tumble 28%
Jun 26We Think The Compensation For Sutro Biopharma, Inc.'s (NASDAQ:STRO) CEO Looks About Right
May 31Bearish: Analysts Just Cut Their Sutro Biopharma, Inc. (NASDAQ:STRO) Revenue and EPS estimates
Apr 02The Market Doesn't Like What It Sees From Sutro Biopharma, Inc.'s (NASDAQ:STRO) Revenues Yet
Mar 28Sutro Biopharma, Inc.'s (NASDAQ:STRO) Price Is Right But Growth Is Lacking After Shares Rocket 43%
Dec 19Is Sutro Biopharma (NASDAQ:STRO) Using Debt In A Risky Way?
Aug 24Is Sutro Biopharma (NASDAQ:STRO) Using Too Much Debt?
Feb 10An Intrinsic Calculation For Sutro Biopharma, Inc. (NASDAQ:STRO) Suggests It's 47% Undervalued
Jan 12Sutro Biopharma: Partnership Progress Warrants Exposure
Aug 16New Forecasts: Here's What Analysts Think The Future Holds For Sutro Biopharma, Inc. (NASDAQ:STRO)
Aug 11Sutro Biopharma GAAP EPS of -$0.55, revenue of $28.1M
Aug 08Sutro to get $10M payment from Merck after first patient dosed in collaboration trial
Jul 26Is Sutro Biopharma (NASDAQ:STRO) Using Too Much Debt?
May 02Sutro; A Biotech To Watch With A Catalyst Rapidly Approaching
Dec 27Is Sutro Biopharma (NASDAQ:STRO) A Risky Investment?
Dec 26CEO Compensation Analysis
| Date | Total Compensation | Salary | Company Earnings |
|---|---|---|---|
| Dec 31 2024 | n/a | n/a | -US$227m |
| Sep 30 2024 | n/a | n/a | -US$124m |
| Jun 30 2024 | n/a | n/a | -US$124m |
| Mar 31 2024 | n/a | n/a | -US$115m |
| Dec 31 2023 | n/a | n/a | -US$107m |
| Sep 30 2023 | n/a | n/a | -US$172m |
| Jun 30 2023 | n/a | n/a | -US$143m |
| Mar 31 2023 | n/a | n/a | -US$130m |
| Dec 31 2022 | US$1m | US$487k | -US$119m |
| Sep 30 2022 | n/a | n/a | -US$123m |
| Jun 30 2022 | n/a | n/a | -US$134m |
| Mar 31 2022 | n/a | n/a | -US$114m |
| Dec 31 2021 | US$4m | US$188k | -US$106m |
Compensation vs Market: Insufficient data to establish whether Jane's total compensation is reasonable compared to companies of similar size in the US market.
Compensation vs Earnings: Jane's compensation has been consistent with company performance over the past year.
CEO
Jane Chung (52 yo)
1.3yrs
Tenure
US$1,432,093
Compensation
Ms. Jane Chung, RPh, served as Chief Commercial Officer of Sutro Biopharma, Inc. since August 09, 2021 until November 2023 and serves as its Chief Operating Officer since November 2023 and also serves as i...
Leadership Team
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| Chief Scientific Officer | 1.5yrs | US$1.63m | 0.037% $ 25.3k | |
| Chief Medical Officer | 2.1yrs | US$2.34m | 0.064% $ 43.7k | |
| President | 1.3yrs | US$1.43m | 0.12% $ 80.9k | |
| Founder | no data | no data | no data | |
| CFO & Secretary | 12.2yrs | US$2.08m | 0.16% $ 108.7k | |
| Chief Technical Operations Officer | 1.8yrs | no data | 0.047% $ 31.6k | |
| General Counsel | 4yrs | no data | no data | |
| Chief People & Communications Officer | 17.2yrs | US$1.30m | 0.13% $ 87.1k | |
| Chief Business Development Officer | less than a year | no data | no data | |
| Vice President & Controller | no data | no data | no data |
2.0yrs
Average Tenure
61.5yo
Average Age
Experienced Management: STRO's management team is not considered experienced ( 2 years average tenure), which suggests a new team.
Board Members
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| Independent Chair of the Board | 5.8yrs | US$173.11k | 0% $ 0 | |
| Independent Director | 5.2yrs | US$138.11k | 0% $ 0 | |
| Independent Director | 11.1yrs | US$138.11k | 0.068% $ 46.4k | |
| Independent Director | 15.6yrs | US$140.11k | 0.027% $ 18.5k | |
| Member of Scientific Advisory Board | 2.2yrs | US$1.53m | no data | |
| Chair of the Scientific Advisory Board | 4.8yrs | no data | no data | |
| Independent Director | 6.7yrs | US$133.11k | 0% $ 0 | |
| Independent Director | 8.1yrs | US$152.11k | 0% $ 0 | |
| Independent Director | 4.3yrs | US$145.11k | 0% $ 0 | |
| Co-Chair of Clinical Advisory Board & Member of Scientific Advisory Board | no data | no data | no data | |
| Member of the Clinical Advisory Board | 4.8yrs | no data | no data | |
| Independent Director | 3.3yrs | US$150.28k | 0% $ 0 |
5.2yrs
Average Tenure
66yo
Average Age
Experienced Board: STRO's board of directors are considered experienced (5.2 years average tenure).
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/03/16 14:44 |
| End of Day Share Price | 2025/03/14 00:00 |
| Earnings | 2024/12/31 |
| Annual Earnings | 2024/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Sutro Biopharma, Inc. is covered by 14 analysts. 11 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Zhiqiang Shu | Berenberg |
| Tazeen Ahmad | BofA Global Research |
| Thomas Shrader | BTIG |